Weekly Recap

Topline Data on NE3017 Announced, Pitolisant Improves EDS in DM1, Nerivio Reduces Migraine Treatment Days

ByNeurologyLive® Staff

December 16th 2023

Neurology News Network for the week ending December 16, 2023. [WATCH TIME: 3 minutes]

Concomitant ASM Dosages With Stiripentol, FDA Pushes Givinostat Decision Back, Soticlestat Improves Caregiver Satisfaction

ByNeurologyLive® Staff

December 9th 2023

Neurology News Network for the week ending December 9, 2023. [WATCH TIME: 3 minutes]

Phase 2 Trial of Alzheimer Psychosis Initiated, FDA Declines to Lift Hold on ENTR-601-44, Levetiracetam and Clobazam With Safety Warnings

ByNeurologyLive® Staff

December 2nd 2023

Neurology News Network for the week ending December 1, 2023. [WATCH TIME: 4 minutes]

FDA Grants BrainStorm Meeting for NurOwn, Gene Therapy Study of AB-1005 Underway, VISION Trial to Test DBS Enhancement in PD

ByNeurologyLive® Staff

November 25th 2023

Neurology News Network for the week ending November 25, 2023. [WATCH TIME: 4 minutes

Valbenazine Shines in Open-Label Extension, FDA Grants Breakthrough Designation to NfL Test, Tocilizumab Effective in NMOSD

ByNeurologyLive® Staff

November 18th 2023

Neurology News Network for the week ending November 18, 2023. [WATCH TIME: 3 minutes]

FDA Clears Modius Sleep Device, NDA Accepted for SPN-830, Zilucoplan Improves Myasthenic Fatigue

ByNeurologyLive® Staff

November 11th 2023

Neurology News Network for the week ending November 11, 2023. [WATCH TIME: 3 minutes]

Migraine Preventive Prescription Trends, TAK-861 Phase 1 Study in Narcolepsy, Simufilam Not Associated With ARIA-E

ByNeurologyLive® Staff

November 4th 2023

Neurology News Network for the week ending November 4, 2023. [WATCH TIME: 3 minutes]

Solanezumab Fails A4 Alzheimer Study, FDA Lifts Hold on FREEDOM-DM1 Trial, CMS Announces Coverages of PET Amyloid-ß Imaging

ByNeurologyLive® Staff

October 21st 2023

Neurology News Network for the week ending October 21, 2023. [WATCH TIME: 3 minutes]

FDA Hands CRL to Patisiran, GBA1 Parkinson Trial Initiated, Levetiracetam Effective as First-Line Treatment in IGE Syndromes

ByNeurologyLive® Staff

October 14th 2023

Neurology News Network for the week ending October 14, 2023. [WATCH TIME: 3 minutes]

FDA Clears High Dose Cohort of CTI-1601, SOMNUM AI Device Approved, Intracranial Pressure Monitoring and TBI

ByNeurologyLive® Staff

October 7th 2023

Neurology News Network for the week ending October 7, 2023. [WATCH TIME: 3 minutes]

AdComm Committee Downvotes NurOwn, ADELY01 Cleared for Trials, Axsome Pushes Back SYMPHONY Trial

ByNeurologyLive® Staff

September 30th 2023

Neurology News Network for the week ending September 30, 2023. [WATCH TIME: 4 minutes]

FDA Approves AIRAscore, Pimavanserin Packing Label Updated, Blarcamesine Data Released

ByNeurologyLive® Staff

September 23rd 2023

Neurology News Network for the week ending September 23, 2023. [WATCH TIME: 3 minutes]

MS Treatments Linked With PML, Neflamapimod Effectiveness Based on P-Tau181 Levels, Nerivio Safe in Pregnant Women

ByNeurologyLive® Staff

September 16th 2023

Neurology News Network for the week ending September 16, 2023. [WATCH TIME: 3 minutes]

CNM-Au8 Improves Survival in ALS, New Parkinson Risk Factor Identified, Pamrevlumab Falls Short in Phase 3 Study

ByNeurologyLive® Staff

September 9th 2023

Neurology News Network for the week ending September 9, 2023. [WATCH TIME: 3 minutes]

Cell Therapy Bemdaneprocel Meets Primary Objective, Retinal Thickness in Parkinson Disease, TERIS Study Findings Published

ByNeurologyLive® Staff

September 2nd 2023

Neurology News Network for the week ending September 2, 2023. [WATCH TIME: 3 minutes]

DT-216 Reduces Frataxin Levels in FA, Valbenazine FDA-Approved for Huntington Chorea, EU Approves Atogepant as Migraine Preventive

ByNeurologyLive® Staff

August 26th 2023

Neurology News Network for the week ending August 26, 2023. [WATCH TIME: 3 minutes]

FDA Approves DaxibotulinumtoxinA for Cervical Dystonia, Genetic Parkinson Trial Announced, DBS Improves Poststroke Mobility

ByNeurologyLive® Staff

August 19th 2023

Neurology News Network for the week ending August 19, 2023. [WATCH TIME: 4 minutes]

Vyvgart Hytrulo Meets Primary End Point, Trial on Fibromyalgia-Type Long COVID Continues, Aspirin Increased Intracranial Bleeding in Elders

ByNeurologyLive® Staff

August 12th 2023

Neurology News Network for the week ending August 12, 2023. [WATCH TIME: 3 minutes]

MS Medications Added to WHO Essential List, Epigenome Therapy Shows Efficacy in AD, Phase 3 NEURO-TTransform Results Announced

ByNeurologyLive® Staff

August 5th 2023

Neurology News Network for the week ending August 5, 2023. [WATCH TIME: 4 minutes]

Positive Data on Dravet Therapy STK-001, FDA Clears Zoom 88 LDP Support, MS Diagnostic Guidelines Updated

ByNeurologyLive® Staff

July 29th 2023

Neurology News Network for the week ending July 29, 2023. [WATCH TIME: 4 minutes]

TRAILBLAZER-ALZ-2 Data of Donanemab Published, Risdiplam Effective in SMA up to 4 Years, Preclinical Alzheimer Study of Lecanemab Announced

ByNeurologyLive® Staff

July 22nd 2023

Neurology News Network for the week ending July 22, 2023. [WATCH TIME: 3 minutes]

Sleeping Pills and Increased Mortality, IPX203 Receives CRL, CT1812 Impacts Brain Function

ByNeurologyLive® Staff

July 8th 2023

Neurology News Network for the week ending July 8, 2023. [WATCH TIME: 3 minutes]

Gene Therapy AMT-130 in Huntington Disease, NDA Submitted for Troriluzole in Spinocerebellar Ataxia, FDA Clears Alzheimer Assays

ByNeurologyLive® Staff

July 1st 2023

Neurology News Network for the week ending July 1, 2023. [WATCH TIME: 3 minutes]

CNM-Au8 Reduces Neurofilament Light, Candesartan Benefits Headache, Ketamine Shows Potential in Migraine

ByNeurologyLive® Staff

June 24th 2023

Neurology News Network for the week ending June 24, 2023. [WATCH TIME: 3 minutes]

Phase 3 LAVENDER Trial Results Published, Protective and Risk Factors of Insomnia, Lecanemab Gets Positive FDA AdComm Review

ByNeurologyLive® Staff

June 17th 2023

Neurology News Network for the week ending June 17, 2023. [WATCH TIME: 3 minutes]

BIIB122 Discontinued in LRRK2 Parkinson Disease, Pimavanserin and PTSD-Associated Insomnia, Obstructive Sleep Apnea Following VNS

ByNeurologyLive® Staff

June 10th 2023

Neurology News Network for the week ending June 10, 2023. [WATCH TIME: 3 minutes]

CMS Adds Coverage for Antiamyloid Therapies, NDA for Migraine Agent Accepted, INTUNE Study Ahead of Schedule

ByNeurologyLive® Staff

June 3rd 2023

Neurology News Network for the week ending June 2, 2023. [WATCH TIME: 3 minutes]

Wave Discontinues ALS Agent WVE-004, FDA Pushes Back Decision on SRP-9001, Asundexian Receives Fast Track Designation

ByNeurologyLive® Staff

May 27th 2023

Neurology News Network for the week ending May 27, 2023. [WATCH TIME: 3 minutes]

Treg Treatment Sustains Cognition in AD, FDA Approves Spinal Cord Stimulation Systems, Soticlestat Reduces Seizures in CDD

ByNeurologyLive® Staff

May 20th 2023

Neurology News Network for the week ending May 20, 2023. [WATCH TIME: 4 minutes]

CVD Risk in Epilepsy Increases Dementia Risk, Teriflunomide in RIS, FDA Clears Dry-Sensor EEG Headset

ByNeurologyLive® Staff

May 13th 2023

Neurology News Network for the week ending May 13, 2023. [WATCH TIME: 4 minutes]

Weekly Recap

Topline Data on NE3017 Announced, Pitolisant Improves EDS in DM1, Nerivio Reduces Migraine Treatment Days

Concomitant ASM Dosages With Stiripentol, FDA Pushes Givinostat Decision Back, Soticlestat Improves Caregiver Satisfaction

Phase 2 Trial of Alzheimer Psychosis Initiated, FDA Declines to Lift Hold on ENTR-601-44, Levetiracetam and Clobazam With Safety Warnings

FDA Grants BrainStorm Meeting for NurOwn, Gene Therapy Study of AB-1005 Underway, VISION Trial to Test DBS Enhancement in PD

Valbenazine Shines in Open-Label Extension, FDA Grants Breakthrough Designation to NfL Test, Tocilizumab Effective in NMOSD

FDA Clears Modius Sleep Device, NDA Accepted for SPN-830, Zilucoplan Improves Myasthenic Fatigue

Migraine Preventive Prescription Trends, TAK-861 Phase 1 Study in Narcolepsy, Simufilam Not Associated With ARIA-E

Solanezumab Fails A4 Alzheimer Study, FDA Lifts Hold on FREEDOM-DM1 Trial, CMS Announces Coverages of PET Amyloid-ß Imaging

FDA Hands CRL to Patisiran, GBA1 Parkinson Trial Initiated, Levetiracetam Effective as First-Line Treatment in IGE Syndromes

FDA Clears High Dose Cohort of CTI-1601, SOMNUM AI Device Approved, Intracranial Pressure Monitoring and TBI

AdComm Committee Downvotes NurOwn, ADELY01 Cleared for Trials, Axsome Pushes Back SYMPHONY Trial

FDA Approves AIRAscore, Pimavanserin Packing Label Updated, Blarcamesine Data Released

MS Treatments Linked With PML, Neflamapimod Effectiveness Based on P-Tau181 Levels, Nerivio Safe in Pregnant Women

CNM-Au8 Improves Survival in ALS, New Parkinson Risk Factor Identified, Pamrevlumab Falls Short in Phase 3 Study

Cell Therapy Bemdaneprocel Meets Primary Objective, Retinal Thickness in Parkinson Disease, TERIS Study Findings Published

DT-216 Reduces Frataxin Levels in FA, Valbenazine FDA-Approved for Huntington Chorea, EU Approves Atogepant as Migraine Preventive

FDA Approves DaxibotulinumtoxinA for Cervical Dystonia, Genetic Parkinson Trial Announced, DBS Improves Poststroke Mobility

Vyvgart Hytrulo Meets Primary End Point, Trial on Fibromyalgia-Type Long COVID Continues, Aspirin Increased Intracranial Bleeding in Elders

MS Medications Added to WHO Essential List, Epigenome Therapy Shows Efficacy in AD, Phase 3 NEURO-TTransform Results Announced

Positive Data on Dravet Therapy STK-001, FDA Clears Zoom 88 LDP Support, MS Diagnostic Guidelines Updated

TRAILBLAZER-ALZ-2 Data of Donanemab Published, Risdiplam Effective in SMA up to 4 Years, Preclinical Alzheimer Study of Lecanemab Announced

Sleeping Pills and Increased Mortality, IPX203 Receives CRL, CT1812 Impacts Brain Function

Gene Therapy AMT-130 in Huntington Disease, NDA Submitted for Troriluzole in Spinocerebellar Ataxia, FDA Clears Alzheimer Assays

CNM-Au8 Reduces Neurofilament Light, Candesartan Benefits Headache, Ketamine Shows Potential in Migraine

Phase 3 LAVENDER Trial Results Published, Protective and Risk Factors of Insomnia, Lecanemab Gets Positive FDA AdComm Review

BIIB122 Discontinued in LRRK2 Parkinson Disease, Pimavanserin and PTSD-Associated Insomnia, Obstructive Sleep Apnea Following VNS

CMS Adds Coverage for Antiamyloid Therapies, NDA for Migraine Agent Accepted, INTUNE Study Ahead of Schedule

Wave Discontinues ALS Agent WVE-004, FDA Pushes Back Decision on SRP-9001, Asundexian Receives Fast Track Designation

Treg Treatment Sustains Cognition in AD, FDA Approves Spinal Cord Stimulation Systems, Soticlestat Reduces Seizures in CDD

CVD Risk in Epilepsy Increases Dementia Risk, Teriflunomide in RIS, FDA Clears Dry-Sensor EEG Headset

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Anti-MTBR Tau Antibody Etalanetug Given FDA Fast Track Designation

Smartphone-Based App for Muscular Relaxation Significantly Reduces Migraine-Related Disability in Emergency Room Settings

Incidence and Prevalence of Frontotemporal Dementia Similar to Dementia with Lewy Bodies, Meta-Analysis Shows

NeurologyLive® Friday 5 — October 24, 2025

Increasing Early Awareness of Child Neurology as a Potential Career Path: Miya Bernson-Leung, MD, EdM